Published in J Mater Sci Mater Med on March 08, 2013
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine (2016) 0.77
A Lanthanum-Tagged Chemotherapeutic Agent HA-Pt to Track the In Vivo Distribution of Hyaluronic Acid Complexes. BAOJ Pharm Sci (2015) 0.75
Synthesis of functionalized Pluronic-b-poly(ε-caprolactone) and the comparative study of their pendant groups on the cellular internalization behavior. J Mater Sci Mater Med (2015) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
Multifunctional nanocarriers. Adv Drug Deliv Rev (2006) 4.46
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet (1994) 3.69
Hyaluronan fragments: an information-rich system. Eur J Cell Biol (2006) 3.26
CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet (1995) 3.07
Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev (2008) 2.87
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine (2006) 2.07
Targeting nanoparticles to cancer. Pharmacol Res (2010) 1.88
De-novo expression of CD44 and survival in gastric cancer. Lancet (1993) 1.75
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm (2005) 1.55
Preparation and properties of fluorescein-labelled hyaluronate. Carbohydr Res (1975) 1.52
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials (2004) 1.51
Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1996) 1.49
Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm (2008) 1.45
Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials (2009) 1.43
In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res (1997) 1.42
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol (2000) 1.33
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol (1995) 1.25
CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood (1995) 1.21
Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer (2001) 1.21
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release (2007) 1.20
Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem (2006) 1.16
Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 1.15
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials (2012) 1.10
Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer (1995) 0.94
Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol (1995) 0.91
Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv (2010) 0.91
Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol (1996) 0.90
High-performance size-exclusion chromatographic procedure for the determination of fluoresceinyl isothiocyanate dextrans of various molecular masses in biological media. J Chromatogr (1989) 0.90
Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology (1995) 0.90
Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer. Gynecol Oncol (1994) 1.42
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer (2004) 1.20
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Effects of fibronectin and laminin on structural, mechanical and transport properties of 3D collageneous network. J Mater Sci Mater Med (2007) 1.02
Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Am J Pathol (1999) 1.01
Patellofemoral malalignment in adolescents. Computerized tomographic assessment with or without quadriceps contraction. Am J Sports Med (1994) 0.98
Carnitine: an osmolyte that plays a metabolic role. J Cell Biochem (2000) 0.96
Effective production of a thermostable alpha-glucosidase from Sulfolobus solfataricus in Escherichia coli exploiting a microfiltration bioreactor. Biotechnol Bioeng (2000) 0.93
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol (2010) 0.93
Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol (2000) 0.90
Childhood hepatocellular tumors in FAP. Gastroenterology (1997) 0.88
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol (1998) 0.88
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res (2007) 0.86
Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers. Eur J Surg Oncol (2004) 0.85
Changes in intestinal permeability to lactulose induced by cytotoxic chemotherapy. Cancer Treat Rep (1982) 0.85
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer (2013) 0.85
Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene. J Clin Endocrinol Metab (2001) 0.85
The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice. Br J Pharmacol (2014) 0.84
Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation. J Cell Physiol (2013) 0.83
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer. Clin Oncol (R Coll Radiol) (2000) 0.83
Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res (1989) 0.81
Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat (1998) 0.81
Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res (1991) 0.80
An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. Ann Oncol (2003) 0.80
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer. Lung Cancer (2000) 0.80
Carnitine protects the molecular chaperone activity of lens alpha-crystallin and decreases the post-translational protein modifications induced by oxidative stress. FASEB J (2001) 0.79
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer. Curr Oncol (2013) 0.79
A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant. Cancer (1996) 0.78
Modulation of in vitro myogenesis induced by different polymer substrates. J Mater Sci Mater Med (2004) 0.78
Medical treatment of resistant or recurrent epithelial ovarian cancer. Ann Oncol (2006) 0.78
Vitronectin absorbed on nanoparticles mediate cell viability/proliferation and uptake by 3T3 Swiss albino mouse fibroblasts: in vitro study. Biomed Res Int (2013) 0.77
Immunogold labelling in environmental scanning electron microscopy: applicative features for complementary cytological interpretation. J Microsc (2011) 0.77
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori (1986) 0.77
[Extramedullary primary cutaneous plasmacytoma. Description of a case] . Recenti Prog Med (2000) 0.76
Surgical treatment of differentiated thyroid carcinoma: a retrospective study. G Chir (2008) 0.76
Cell division cycle alterations and human tumors. Adv Exp Med Biol (1999) 0.76
Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan. Ann Oncol (2007) 0.75
[Solitary gastric plasmacytoma. Case report and review of the literature]. Minerva Chir (1994) 0.75
[Torsional changes in the lower limbs in childhood]. Arch Putti Chir Organi Mov (1990) 0.75
[Metaphyseal and diaphyseal fractures of the femur resulting in growth inequality in children under 3 years of age]. Arch Putti Chir Organi Mov (1991) 0.75
[Popliteal cysts in young children]. Arch Putti Chir Organi Mov (1984) 0.75
[Enzymatic changes in the lymph in the thoracic duct and right lymphatic duct during extracorporeal circulation in the dog (author's transl)]. J Chir (Paris) (1977) 0.75
[Lymphatic drainage during extracorporeal circulation and hypothermic circulatory arrest in dogs. Analysis of the lymph and technic of catheterization of the duct by thoracic approach through the innominate vein]. Arch Chir Torac Cardiovasc (1977) 0.75
[Reoperation in lumber disk hernia pathology]. Arch Putti Chir Organi Mov (1980) 0.75
[Dynamic arthrography of the hip in childhood]. Arch Putti Chir Organi Mov (1984) 0.75
["Snapping finger" in childhood: etiopathogenesis, pathologic anatomy, therapy]. Arch Putti Chir Organi Mov (1984) 0.75
[Treatment of malleolar fractures]. Arch Putti Chir Organi Mov (1977) 0.75
Subcutaneous seeding of hepatocellular carcinoma after fine-needle percutaneous biopsy. J Clin Gastroenterol (2001) 0.75
Expression of CD40 has no predictive value in soft tissue sarcomas. Anticancer Res (2003) 0.75
A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications. Ann Oncol (2005) 0.75
Clinical studies with B72.3 in ovarian cancer and probe-guided tumor localization. Int J Rad Appl Instrum B (1991) 0.75
Carnitine system and tumor. Adv Exp Med Biol (1999) 0.75
The role of integrative and complementary medicine in the management of breast cancer patients on behalf of the Integrative Medicine Research Group (IMRG). Eur Rev Med Pharmacol Sci (2022) 0.75
[Congenital metatarsus varus]. Arch Putti Chir Organi Mov (1989) 0.75
[Cancer risk in breast lesions: diagnostic and therapeutic strategy]. Minerva Chir (2003) 0.75
HLA and prognostic factors in primary breast cancer. Int J Cancer (1985) 0.75
[Tissue engineering of parathyroid gland]. G Chir (2010) 0.75
Partial response of metastatic hepatocellular carcinoma after treatment with thymostimulin. Tumori (1990) 0.75
Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease. Gynecol Oncol (1993) 0.75
Changing presentation in non-Hodgkin lymphoma. Lancet (1990) 0.75
["Short" orthotopic autologous transplantation of the small intestine in dogs. Results after 10 months]. Minerva Chir (1978) 0.75
[Extracorporeal perfusion through the extra-situ isolated liver in the treatment of severe hepatic insufficiency]. Minerva Chir (1978) 0.75
Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. Eur J Nucl Med (1991) 0.75
[Surgical treatment of diaphyseal fractures of the forearm during pre-adolescent age]. Arch Putti Chir Organi Mov (1991) 0.75
Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study. Eur J Cancer (1994) 0.75
[Opaque arthrography of the knee in the diagnosis of meniscal lesions]. Arch Putti Chir Organi Mov (1981) 0.75
[The indications for and limits of "extensive" posterior lysis in the surgical treatment of congenital clubfoot (talipes equinovarus supinatus)]. Arch Putti Chir Organi Mov (1991) 0.75
Intermittent chemotherapy in advanced colorectal cancer: is it the future? Colorectal Dis (2012) 0.75
[Rare skeletal pathology: the diagnostic problems in the first year of life]. Arch Putti Chir Organi Mov (1990) 0.75
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers (1991) 0.75
CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: final results of a pilot study. Hematol Oncol (1991) 0.75
[Opaque arthrography in the study of meniscal lesions: diagnostic interpretative problems]. Radiol Med (1981) 0.75
Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement. Clin Oncol (R Coll Radiol) (1994) 0.75
The treatment of metastatic pleural effusion in breast cancer: report of 25 cases. Tumori (1987) 0.75
[Clinical and pathogenetic observations on the lumbar herniated disk syndrome in the aged]. Arch Putti Chir Organi Mov (1978) 0.75
Pain and sensory dysfunction after breast cancer surgery: neurometer CPT evaluation. Anticancer Res (2006) 0.75
[Surgical treatment of pseudarthrosis of the scaphoid of the wrist]. Arch Putti Chir Organi Mov (1978) 0.75
Synthesis and characterisation of poly(2-hydroxyethyl methacrylate) polyelectrolyte complexes. J Mater Sci Mater Med (2004) 0.75
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study. Anticancer Res (2002) 0.75
[ulnar nerve neuropathy at the epitrochlear sulcus]. Arch Putti Chir Organi Mov (1980) 0.75